Last $71.33 USD
Change Today -2.13 / -2.90%
Volume 1.0M
PTCT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

ptc therapeutics inc (PTCT) Snapshot

Open
$70.50
Previous Close
$73.46
Day High
$75.94
Day Low
$69.76
52 Week High
02/27/15 - $75.94
52 Week Low
05/21/14 - $14.51
Market Cap
2.4B
Average Volume 10 Days
912.0K
EPS TTM
$-3.21
Shares Outstanding
33.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PTC THERAPEUTICS INC (PTCT)

ptc therapeutics inc (PTCT) Related Bloomberg News

View More Bloomberg News

ptc therapeutics inc (PTCT) Details

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. Its lead product candidate is ataluren for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutations or nmCF. The company had completed a Phase IIb clinical trial of ataluren for the treatment of nmDMD and a Phase III clinical trial of ataluren for the treatment of nmCF. In addition, it develops spinal muscular atrophy, which is in Phase I clinical program. The company’s preclinical development programs include PTC596, a development candidate used for the treatment of chemotherapy resistant cancers; and antibacterial small molecule compounds for the treatment of life-threatening infections caused by multidrug-resistant Gram-negative bacteria. PTC Therapeutics, Inc. has collaborations with Roche and the SMA Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; and AstraZeneca AB for the discovery and development of potential new therapies for cancer and other diseases. The company was founded in 1998 and is based in South Plainfield, New Jersey.

133 Employees
Last Reported Date: 03/6/14
Founded in 1998

ptc therapeutics inc (PTCT) Top Compensated Officers

Co-Founder, Chief Executive Officer and Execu...
Total Annual Compensation: $460.8K
Chief Commercial Officer
Total Annual Compensation: $368.2K
Compensation as of Fiscal Year 2013.

ptc therapeutics inc (PTCT) Key Developments

Investors Reportedly Eyes Stake In PTCT

PTC Therapeutics, Inc. (NasdaqGS:PTCT) is exploring a potential sale amid takeover interest from Shire plc (LSE:SHP) and BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), according to people familiar with the matter. PTCT is working with financial advisers as it weighs strategic alternatives, said the sources, who asked not to be named because the matter is private. Representatives for could not be reached for comment. Representatives for Shire and BioMarin declined to comment. Shire Plc could be interested in acquiring PTC Therapeutics to add to its portfolio of rare disease drugs, the sources added.

PTC Therapeutics, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015

PTC Therapeutics, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.

PTC Therapeutics, Inc., Q4 2014 Earnings Call, Feb 27, 2015

PTC Therapeutics, Inc., Q4 2014 Earnings Call, Feb 27, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTCT:US $71.33 USD -2.13

PTCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTCT.
View Industry Companies
 

Industry Analysis

PTCT

Industry Average

Valuation PTCT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 126.8x
Price/Book 10.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 132.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PTC THERAPEUTICS INC, please visit www.ptcbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.